ReviewThe Kaohsiung journal of medical sciences2026
Metabolic Dysfunction-Associated Steatotic Liver Disease After Hepatitis C Virus Cure.
Review in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatitis C virus (HCV) infection is an infectious disease carrying a high risk of metabolic disorders. Chronic HCV (CHC) patients can possess extrahepatic manifestations such as diabetes, steatotic liver disease (SLD), and other metabolic alterations. Hepatic steatosis, which is triggered by insulin resistance or the direct insult of a specific genotype, is commonly observed in CHC. The changes in SLD after HCV eradication by direct-acting antivirals (DAAs) present a significant impact on patient outcomes. We reviewed the changes in cardiometabolic risk factors (CMRFs) and the evolution of CMRFs items in CHC patients with SLD after HCV cure. The reassessment of CMRFs after the successful eradication of HCV is an essential task for primary care providers. CHC patients could benefit from appropriate management of both infectious and metabolic disorders in terms of liver and nonliver related outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.